The market taxonomy for Alzheimer’s Disease Therapeutics and Diagnostics segmentation also classifies diagnostic solutions by type—neuroimaging modalities (MRI, PET), fluid‑based biomarkers (CSF, blood), and genetic‑testing platforms that assess risk alleles such as APOE ε4. Application‑level categories separate these technologies into early detection, differential diagnosis, and longitudinal disease monitoring. Early‑detection tools, particularly blood‑based amyloid and tau assays, are expanding rapidly because they enable population‑screening at lower cost, thereby enlarging the addressable market and attracting payer coverage. Differential‑diagnosis products, chiefly PET imaging combined with CSF profiling, retain premium pricing due to their high specificity in distinguishing Alzheimer’s from other dementias, contributing disproportionately to diagnostic revenue despite a smaller patient pool. Disease‑monitoring solutions, including serial MRI volumetrics and plasma neurofilament light measurements, support therapeutic decision‑making and are increasingly bundled into value‑based contracts, generating steady recurring income. Collectively, these application segments drive the overall diagnostics market size, with each sub‑segment’s growth reflecting clinical adoption curves and reimbursement evolution.
